APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Endothelial Growth Factor (VEGF) Antibodies

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Research Report 2026

31 December 2025129 pages

Choose your research edition.

Industry ResearchVascular Endothelial Growth Factor (VEGF) Antibodies Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Endothelial Growth Factor (VEGF) Antibodies Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Vascular Endothelial Growth Factor (VEGF) Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Vascular Endothelial Growth Factor (VEGF) Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Vascular Endothelial Growth Factor (VEGF) Antibodies is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Vascular Endothelial Growth Factor (VEGF) Antibodies is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies include Sanofi, Novartis, Merck, Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Vascular Endothelial Growth Factor (VEGF) Antibodies market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Company

Sanofi

Novartis

Merck

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Regeneron

Bristol-Myer Squibb

Boehringer Ingelheim

Abcam Plc

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Type

Aflibercept

Bevacizumab

Ranibizumab

Others

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Application

Specialty Clinics

Hospitals

Ambulatory Surgical Centers

Cancer Research Institutes

Others

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Endothelial Growth Factor (VEGF) Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Endothelial Growth Factor (VEGF) Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Endothelial Growth Factor (VEGF) Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Vascular Endothelial Growth Factor (VEGF) Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Vascular Endothelial Growth Factor (VEGF) Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Manufacturers (2021-2026) Table 8. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue of Manufacturers (2021-2026) Table 9. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Vascular Endothelial Growth Factor (VEGF) Antibodies Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies, Product Type & Application Table 14. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Vascular Endothelial Growth Factor (VEGF) Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 22. Sanofi Recent Developments Table 23. Novartis Company Information Table 24. Novartis Business Overview Table 25. Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 27. Novartis Recent Developments Table 28. Merck Company Information Table 29. Merck Business Overview Table 30. Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 32. Merck Recent Developments Table 33. Roche Company Information Table 34. Roche Business Overview Table 35. Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 37. Roche Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 47. Pfizer Recent Developments Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 52. GlaxoSmithKline Recent Developments Table 53. Bayer Company Information Table 54. Bayer Business Overview Table 55. Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 57. Bayer Recent Developments Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 62. AstraZeneca Recent Developments Table 63. Regeneron Company Information Table 64. Regeneron Business Overview Table 65. Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 67. Regeneron Recent Developments Table 68. Bristol-Myer Squibb Company Information Table 69. Bristol-Myer Squibb Business Overview Table 70. Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 72. Bristol-Myer Squibb Recent Developments Table 73. Boehringer Ingelheim Company Information Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 77. Boehringer Ingelheim Recent Developments Table 78. Abcam Plc Company Information Table 79. Abcam Plc Business Overview Table 80. Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio Table 82. Abcam Plc Recent Developments Table 83. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 84. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2021-2026) & (W Units) Table 85. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Region (2021-2026) Table 86. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2027-2032) & (W Units) Table 87. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Region (2027-2032) Table 88. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 89. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region (2021-2026) Table 90. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 91. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region (2027-2032) Table 92. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 94. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 95. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 96. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 97. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 99. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 100. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 102. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 104. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 105. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 106. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 107. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 109. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 110. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 111. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 112. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2026) & (W Units) Table 114. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2027-2032) & (W Units) Table 115. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2026) & (US$ Million) Table 116. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2027-2032) & (US$ Million) Table 117. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021-2026) & (W Units) Table 118. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2027-2032) & (W Units) Table 119. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2021-2026) Table 120. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2027-2032) Table 121. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2021-2026) & (US$ Million) Table 122. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2027-2032) & (US$ Million) Table 123. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2021-2026) Table 124. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2027-2032) Table 125. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Type (2021-2026) & (US$/Unit) Table 126. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Type (2027-2032) & (US$/Unit) Table 127. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021-2026) & (W Units) Table 128. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2027-2032) & (W Units) Table 129. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2021-2026) Table 130. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2027-2032) Table 131. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2021-2026) & (US$ Million) Table 132. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2027-2032) & (US$ Million) Table 133. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2021-2026) Table 134. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2027-2032) Table 135. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Application (2021-2026) & (US$/Unit) Table 136. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Application (2027-2032) & (US$/Unit) Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. Vascular Endothelial Growth Factor (VEGF) Antibodies Distributors List Table 140. Vascular Endothelial Growth Factor (VEGF) Antibodies Customers List Table 141. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Trends Table 142. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Drivers Table 143. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Restraints Table 144. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vascular Endothelial Growth Factor (VEGF) Antibodies Product Image Figure 5. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size (2021-2032) & (US$ Million) Figure 7. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (2021-2032) & (W Units) Figure 8. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Price (US$/Unit) & (2021-2032) Figure 9. Aflibercept Product Image Figure 10. Bevacizumab Product Image Figure 11. Ranibizumab Product Image Figure 12. Others Product Image Figure 13. Specialty Clinics Product Image Figure 14. Hospitals Product Image Figure 15. Ambulatory Surgical Centers Product Image Figure 16. Cancer Research Institutes Product Image Figure 17. Others Product Image Figure 18. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Vascular Endothelial Growth Factor (VEGF) Antibodies Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region in 2025 Figure 24. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region in 2025 Figure 25. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country in 2025 Figure 26. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 27. North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Country (2021-2032) Figure 28. United States Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country in 2025 Figure 31. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 32. Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Country (2021-2032) Figure 33. Germany Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country in 2025 Figure 39. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Country (2021-2032) Figure 41. China Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country in 2025 Figure 50. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 51. South America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Country (2021-2032) Figure 52. Mexico Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country in 2025 Figure 56. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Country (2021-2032) Figure 57. Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Country (2021-2032) Figure 58. Turkey Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. UAE Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2021-2032) Figure 62. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2021-2032) Figure 63. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price (US$/Unit) by Type (2021-2032) Figure 64. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2021-2032) Figure 65. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2021-2032) Figure 66. Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price (US$/Unit) by Application (2021-2032) Figure 67. Vascular Endothelial Growth Factor (VEGF) Antibodies Value Chain Figure 68. Vascular Endothelial Growth Factor (VEGF) Antibodies Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Opportunities and Challenges

Scope & coverage.

Types
  • Aflibercept
  • Bevacizumab
  • Ranibizumab
  • Others
Applications
  • Specialty Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Others
Companies covered
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Regeneron
  • Bristol-Myer Squibb
  • Boehringer Ingelheim
  • Abcam Plc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size (2021-2032)
  4. 2.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (2021-2032)
  5. 2.2.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Average Price (2021-2032)
  6. 2.3 Vascular Endothelial Growth Factor (VEGF) Antibodies by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Aflibercept
  9. 2.3.3 Bevacizumab
  10. 2.3.4 Ranibizumab
  11. 2.3.5 Others
  12. 2.4 Vascular Endothelial Growth Factor (VEGF) Antibodies by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Specialty Clinics
  15. 2.4.3 Hospitals
  16. 2.4.4 Ambulatory Surgical Centers
  17. 2.4.5 Cancer Research Institutes
  18. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies, Product Type & Application
  8. 3.8 Global Manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies, Established Date
  9. 3.9 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Novartis
  8. 4.2.1 Novartis Company Information
  9. 4.2.2 Novartis Business Overview
  10. 4.2.3 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  12. 4.2.5 Novartis Recent Developments
  13. 4.3 Merck
  14. 4.3.1 Merck Company Information
  15. 4.3.2 Merck Business Overview
  16. 4.3.3 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  18. 4.3.5 Merck Recent Developments
  19. 4.4 Roche
  20. 4.4.1 Roche Company Information
  21. 4.4.2 Roche Business Overview
  22. 4.4.3 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  24. 4.4.5 Roche Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 GlaxoSmithKline
  38. 4.7.1 GlaxoSmithKline Company Information
  39. 4.7.2 GlaxoSmithKline Business Overview
  40. 4.7.3 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  42. 4.7.5 GlaxoSmithKline Recent Developments
  43. 4.8 Bayer
  44. 4.8.1 Bayer Company Information
  45. 4.8.2 Bayer Business Overview
  46. 4.8.3 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  48. 4.8.5 Bayer Recent Developments
  49. 4.9 AstraZeneca
  50. 4.9.1 AstraZeneca Company Information
  51. 4.9.2 AstraZeneca Business Overview
  52. 4.9.3 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  54. 4.9.5 AstraZeneca Recent Developments
  55. 4.10 Regeneron
  56. 4.10.1 Regeneron Company Information
  57. 4.10.2 Regeneron Business Overview
  58. 4.10.3 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  60. 4.10.5 Regeneron Recent Developments
  61. 4.11 Bristol-Myer Squibb
  62. 4.11.1 Bristol-Myer Squibb Company Information
  63. 4.11.2 Bristol-Myer Squibb Business Overview
  64. 4.11.3 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  66. 4.11.5 Bristol-Myer Squibb Recent Developments
  67. 4.12 Boehringer Ingelheim
  68. 4.12.1 Boehringer Ingelheim Company Information
  69. 4.12.2 Boehringer Ingelheim Business Overview
  70. 4.12.3 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  72. 4.12.5 Boehringer Ingelheim Recent Developments
  73. 4.13 Abcam Plc
  74. 4.13.1 Abcam Plc Company Information
  75. 4.13.2 Abcam Plc Business Overview
  76. 4.13.3 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
  78. 4.13.5 Abcam Plc Recent Developments
5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Scenario by Region
  1. 5.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region: 2021-2032
  3. 5.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region: 2021-2026
  4. 5.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region: 2027-2032
  5. 5.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region: 2021-2032
  6. 5.3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region: 2021-2026
  7. 5.3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region: 2027-2032
  8. 5.4 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
  9. 5.4.1 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  11. 5.4.3 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
  15. 5.5.1 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  17. 5.5.3 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
  35. 5.7.1 South America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  37. 5.7.3 South America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021-2032)
  2. 6.1.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2021-2032)
  4. 6.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2021-2032)
  5. 6.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021-2032)
  2. 7.1.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2021-2032)
  4. 7.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2021-2032)
  5. 7.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Value Chain Analysis
  2. 8.1.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Production Mode & Process
  5. 8.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Distributors
  8. 8.2.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Customers
9 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Analyzing Market Dynamics
  1. 9.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Trends
  2. 9.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Drivers
  3. 9.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Opportunities and Challenges
  4. 9.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst